Recent evidences suggest that Ab peptides modulate endothelial cell (EC) functions. At low concentrations, Ab 1-40 enhances the pro-angiogenic activity of FGF-2, whereas deposition of excess Ab causes EC dysfunction and cerebral amyloid angiopathy (CAA). We investigated whether FGF-2 attenuates EC dysfunction caused by pathological Ab levels. We studied Ab 1-40 on EC survival, as well as on signals responsible of their angiogenic phenotype. At 5-50 lM Ab 1-40 reduced EC population, caused apoptosis, downregulated FGF-2 production, inhibited FGF-2 binding to heparin, and FGFR1 phosphorylation. Toxic effects were owing to lack of FGF-2 stimulation, as EC overexpressing FGF-2 displayed extraordinary resistance to Ab 1-40 injuries. The FGF-2 mechanism responsible for reversing damages, involves the downstream enhancement of Akt, a pathway independent of eNOS activation.
Introduction
b amyloid peptides (Ab peptides), regarded as the main causative factors of cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD), [1] [2] [3] [4] originate from the amyloid precursor protein (APP) through a proteolytic cascade which generates two peptides of different sequence lengths: Ab and Ab 1-42 . 5 Ab , being primarily vasculotropic, is found in the brain vasculature of CAA patients and in experimental models of the disease, whereas Ab 1-42 , endowed with distinct trophism for neurons, predominates in the brain parenchyma of AD patients. [6] [7] [8] [9] Brain vascular degeneration, typical of both sporadic and genetic variants of CAA, is characterized by perivascular deposition of Ab in cortical and leptomeningeal vessels. 9 The hallmark pathological lesion of these diseases is the pervasive dysfunction of brain capillary endothelium. The dysfunction, clearly related to the toxic effects exerted by Ab 1-40 on endothelial cells (ECs), has been extensively described in cultured cells, 10 in isolated vessels 11 as well as in whole animals. 12 Amyloid peptides induce, at fairly high concentrations, seemingly irreversible changes of morphology and functions of ECs, 13, 14 the latter resulting in reduced survival and suppression of their inherent angiogenic properties.
Besides the overwhelming evidence for a pathological role of Ab peptides, recent studies have revealed also their benign side, which has been seen both in neurons 15 and in the endothelium. 16 Recently, we reported a marked activation of EC basic functions (proliferation, migration) by physiological concentrations (nanomolar) of Ab peptides. 16 Surprisingly, we also uncovered a specific interaction, and indeed a striking synergism, between Ab peptides and fibroblast growth factor-2 (FGF-2). This interaction promotes the intracellular synthesis of FGF-2, yielding an enhanced viability of microvascular endothelium, as well as the expression of robust angiogenic responses. 16 These findings raise the question whether the endothelial toxic injuries exhibited by pathological concentrations of Ab 1-40 might be linked to an impairment of the production of FGF-2, a growth factor crucially implicated in the survival/repair mechanisms of the endothelium. 17 A related question is whether FGF-2 overexpression could prevent the endothelial dysfunction invariably associated with the progression of CAA. To answer these questions, we selected a moderately high concentration of Ab , producing borderline toxic effects on cells, examining its influence on cell viability, endogenous FGF-2 production, and EC responsiveness to other angiogenic factor such as VEGF. We, also, examined how ECs, specifically engineered to overexpress FGF-2, would counteract the Ab peptides toxic lesions and the mechanisms implicated in FGF-2-induced protection, analysing ERK1/2 and Akt phosphorylation, as well as eNOS activity. The evidence gathered in this study clearly indicates that FGF-2 reverts endothelial dysfunction, suggesting that its delivery to injured cells might be a useful therapeutic intervention to attenuate the progression of CAA. characteristics. We selected three cell lines: CVEC, microvascular ECs isolated from bovine postcapillary venular vessels, MAE, macrovascular ECs, from mouse aorta, and pZIPbFGF, a cell line derived from MAE, which express high levels of M r 18, 22 and 24 kDa FGF-2 isoforms under the control of the Mo-MuLV LTR elements of the pZIPNeoSV(X) vector, 17 and release approximately 100 pg/96 h/10 6 cells, as evaluated by immunoassay. 18 In the survival experiments, the initial conditions (confluence, quiescence) were comparable for all lines examined.
The pattern of cell survival differed greatly among cell types, particularly at low micromolar concentrations of Ab . At 0.5 mM, Ab 1-40 did not affect the survival of either pZIPbFGF or CVEC (Figure 1a) . Indeed, in the latter cell line we observed a significant (Po0.01) stimulatory effect, undoubtedly the tailend of pro-proliferative activity recently observed at peptide nanomolar concentrations. 16 In contrast, the cell loss was severe in MAE (60% at 5 mM), and worsened up to 75 and 97% with the rise of peptide concentrations (50 and 100 mM, respectively) ( Figure 1a ). In CVEC, the ability to survive was reduced starting from 5 mM of Ab 1-40 (40% loss), declining gradually thereafter (60 and 90% loss at 50 and 100 mM, respectively) ( Figure 1a ). The decline of survival capacity was significantly lower in pZIPbFGF relative to the other cell lines, being nil at 5, 35% at 50 (Po0.001), and 50% at 100 mM (Po0.001) (Figure 1a) . The reverse-sequence Ab 40-1 (50 mM, not shown) did not affect survival in any cell lines, indicating Ab 1-40 specificity. As we were interested in relating our investigation to the initial, possibly reversible, events of the microvascular pathology, we performed most studies at 5 mM peptide, which produced borderline endothelial cell injury.
In light of the observed cell loss, we investigated whether Ab 1-40 might induce cell death through caspase cascade. Ab 1-40 (5 mM for 16 h) induced in CVEC caspase-3 activation (36%, Po0.01) (Figure 1b ). Caspase-3 activation was revealed also by immunohistochemistry staining which evidenced an increased fluorescence in cell population treated with Ab 1-40 (5 mM), whereas, the lower concentration (0.5 mM), and its reverse peptide showed the same fluorescence pattern as cells cultured in 0.1% BCS (Figure 1c ).
Ab 1-40 impairs FGF-2 production and endothelial cell survival: reversal by engineered overexpression of FGF-2
Because the above experiments hinted to the dependence of cell survival from FGF-2, we examined its endogenous production in all cell lines, following their exposure to Ab in the 0.5-50 mM range. In CVEC, a detectable decline of FGF-2 production occurred at 5 mM (47% versus control), whereas in MAE the expression was abolished at this concentration (96% versus control), the decrease being noticeable even at 0.5 mM (Figure 2a and b) . In contrast, Ab 1-40 marginally affected the FGF-2 expression in pZIPbFGF, as significant decline was observed only at 50 mM (Figure 2c ).
Based on this evidence, showing the importance of FGF-2 in preserving endothelial integrity, we hypothesized that overexpression of endogenous FGF-2 production would overcome the Ab 1-40 -induced decline of angiogenic drive. To test this hypothesis, we compared MAE and pZIPbFGF, seeded on fibrin-embedded microcarriers, for their ability to generate pseudocapillaries in the presence/absence of Ab 1-40 (5 mM) (Figure 2d ). Pseudocapillaries were strikingly more abundant in pZIPbFGF than in MAE (141712 versus 3675, Po0.001). Exposure to Ab 1-40 reduced pseudocapillaries formation in MAE (76% inhibition, Po0.01), whereas in pZIPbFGF a slight sprouting increase was noted ( þ 40%, Po0.01) (Figure 2d ). Pictures of endothelial sprouts emanating radially from Ab 1-40 -treated microcarriers, show a faint pseudocapillary network in MAE, contrasting with the rich sprouting obtained in FGF-2 transfectants (Figure 2e ). Collectively, these data provide evidence for a FGF-2 role in promoting endothelial sprouting and in preserving the angiogenic phenotype in face of Ab-induced injuries.
As Ab appears to target the FGF-2 pathway to induce endothelial toxicity, we examined whether the peptide would interfere with its membrane binding sites. First, we measured the Ab 1-40 ability to influence FGF-2 binding in vitro to heparin, a membrane molecule which functions as an intermediate site for the factor. 19 Pre-incubation with Ab 1-40 (0.05-50 mM) inhibited FGF-2 (25 ng) binding to heparin-coated beads in a concentration-dependent manner (Figure 2f ). This indicates that the FGF-2 binding to its intermediate storage sites is severely affected by Ab 1-40 concentrations higher than 5 mM. Next, we examined whether Ab would affect the activation of the FGF-2 receptor subtype 1. In CHO cells transfected with mouse FGFR1, exposure to the peptide halved the phosphorylation of the receptor at 0.5 mM and reduced it approximately tenfold at 5 mM (OD: 0.86, 0.43, 0.12 for 0.05, 0.5 and 5 mM, respectively, versus 1.07 for FGF-2) (Figure 2g ). (Table 1) . Similarly, the amyloid peptide exerted a profound inhibitory effect on the VEGF-enhanced cell migration (Po0.001) ( Table 1) , and on the release of MMPs (data not shown).
VEGF is known to stimulate the angiogenic phenotype in CVEC through the enhanced expression of FGF-2 and eNOS activation. 20 VEGF-induced expression of both these signals was found to be severely abated by Ab 1-40 (5 mM), which reduced their expression to levels below control (eNOS: 3000 versus 7000 DPM/mg; FGF-2 expression OD: 0.28 versus 0.9) (Figure 3a and b, respectively). Similarly, Ab , which had no effect on ERK1/2 phosphorylation in quiescent cells, markedly attenuated that stimulated by VEGF, reproducing in biochemical terms the effects noted on cell growth (Figure 3c ). Ab 1-40 -induced impairment of functions was also reflected on in vivo angiogenesis. To mimic amyloid pathological deposition, we enriched the corneal stroma of rabbits by delivering Ab 1-40 through implanted micropellets, prior the VEGF challenge. Ab 1-40 dose-dependently (50-500 ng/pellet) reduced the VEGF-promoted angiogenesis, resulting in significantly lower angiogenic scores (Figure 3d ). Ab peptide, when tested alone, did not produce any inflammatory or angiogenic response.
FGF-2 protects from Ab 1-40 toxicity by enhancing Akt phosphorylation
Because the above experiments clearly illustrated the protection of FGF-2 toward Ab 1-40 toxicity, we further analyzed its mechanism, by monitoring Akt, a signal implicated in endothelial survival. 21 FGF-2 (20 ng/ml) promoted Akt phosphorylation with maximal activity at 15 min (Figure 4a ). Ab 1-40 (5 mM), at this time point, sharply reduced (72%, Po0.01) Akt phosphorylation in CVEC (Figure 4a ). FGF-2 application prevented the effect of b amyloid on Akt activity (Po0.01) and, on the contrary, promoted Akt phosphorylation by 52% compared to the basal condition (0.1% serum) (Figure 4a) .
The consequences of interfering with the survival signal changes were revealed by Tunel assay in CVEC exposed to (Figure 4d) . Consistent with the above results, the constitutive eNOS activity was severely inhibited by Ab (5 mM) in MAE and pZIPbFGF clones and remained insensitive to simultaneous FGF-2 application (Figure 4e ), indicating that in the presence of Ab , neither external nor endogenous FGF-2 engages eNOS for their survival.
These results demonstrate that FGF-2 promotes endothelial survival through activation of Akt with a mechanism independent from eNOS activation.
Discussion
Disruption of angiogenesis is regarded as one of the mechanisms contributing to the development of CAA. FGF-2 and beta amyloid S Donnini et al be prevented/repaired by conditions that favour the overexpression of FGF-2. Vascular ECs, although susceptible to toxic injuries caused by Ab peptides, appear to possess an extraordinary resilience to external insults. This feature, not reported before, is attributed to a survival programme driven by the endogenous synthesis of FGF-2, which acts in autocrine-paracrine mode to maintain cell viability.
Ab 1-40 did exert toxic effects on ECs as indicated by the decline of cell population and by the reduced viability. Cell loss caused by Ab 1-40 occurred in a concentration-related fashion in the micromolar range. Interestingly, sub-micromolar concentrations (0.5 mM) evoked growth rather than loss in CVEC, an effect related to a specific interaction of Ab peptides with FGF-2, previously reported from this laboratory. 16 A number of studies have previously described the Ab peptide toxicity on the endothelium with similar results. 11, 23 Emerging from this study is the different sensitivity to Ab 1-40 between cells originating from large vessels exemplified by MAE, and ECs derived from microvessels such as CVEC. An even greater resistance to Ab was observed in the FGF-2 transfectant cell line, that is, pZIPbFGF, a finding that offered the first clue for the importance of FGF-2 in fostering cell survival (see below). EC loss induced by Ab was certainly owing to the documented activation of the pro-apoptotic caspase-3 activity, a finding also described in previous studies. [24] [25] The precipitating event leading to Ab 1-40 -induced endothelial dysfunction, is the reduced production of FGF-2 noted at varying degrees in all EC lines exposed to the peptide. The FGF-2 decline, greater in MAE and CVEC (in this order) than in pZIPbFGF cells, remarkably coincides with their respective survival capacity when exposed to Ab . The relationship between FGF-2 expression and the ability of the endothelium to withstand Ab injuries is strengthened by the sharp differences in pseudocapillary sprouting noted between MAE and pZIPbFGF. Ab 1-40 abolished pseudo-capillaries sprouting in MAE, whereas in pZIPbFGF sprouting remained as florid as in controls. Consistently, FGF-2 has been found to afford protection toward the endothelial damage produced by gp120, an HIV-derived cytoxic protein, 26 as well as to shield neuronal cells from the excitotoxicity induced by Ab peptides. 27 Conceivably, a mechanism that explains the Ab 1-40 toxicity, is the observed disruption of the FGF-2 binding to heparin, a membrane molecule that regulates its subsequent binding to the high-affinity receptor. 19 The marked reduction of FGFR1 phosphorylation following exposure to Ab 1-40 , constitutes prima facie evidence that the above mechanism may be operant and may trigger the toxic injuries, as it deprives the endothelium of the tonic FGF-2 input necessary for its survival.
Rescuing endothelial dysfunction, at least that caused by pathological Ab, appears to be a specific property of FGF-2, VEGF, a growth factor that potently activates ECs 28, 29 failed to restore signals such as eNOS activity, ERK1/2 phosphorylation and FGF-2 production, severely muted by Ab 1-40 application. Indeed, the peptide inhibited in a dose-related fashion the in vivo angiogenic response to VEGF in rabbits. Thus, FGF-2, acting in autocrine-paracrine manner, emerges as a molecule endowed with the role of maintaining cell viability and preventing/repairing lesions caused by noxious agents.
Analysis of signals such as Akt, known to be part of the FGF-2 signaling cascade, and eNOS provided evidence for their relative importance in fostering endothelial survival. Akt, a kinase that acts as a brake to apoptotic proteins, was found to be inherently activated in CVEC, possibly through the tonic input of endogenous FGF-2, and further stimulated by exogenous supply of the growth factor. Interference of Ab 1-40 with FGF-2 binding to heparin and/or FGFR, explains the suppression of Akt phosphorylation, because it prevents message transmittal. Notable, however, was the ability of excess exogenous FGF-2 to completely recover Akt activity. Others have reported a partial reversal of intracellularly generated Ab 1-42 injuries by Akt in HUVEC, 30 although the significance of endogenously generated Ab 1-42 is questionable in endothelium.
Thus, the activation of Akt signals the survival program operated by FGF-2 to revert apoptosis induced by Ab .
eNOS, a well-recognized promoter of endothelial integrity and survival, 20, 31 was inhibited by Ab in its ability to produce NO through enzymatic activity. However, at variance with Akt, this signal was not restored by exogenous FGF-2. Tentatively, the inhibition of eNOS may be linked to the suppression of HSP90/eNOS complex found in cells treated with Ab , as this chaperon protein is essential for eNOS activation. 32 How the amyloid might influence HSP90/eNOS complex is a matter of further investigation. Collectively, the studies on signals helped in delineating the FGF-2 pathway as an autocrine mechanism capable to rescue ECs from damages caused by Ab independently from the eNOS pathway.
The evidence here reported, showing the crucial role of FGF-2 expression in reverting Ab-induced lesions, has implications for strategies that aim at reducing the burden of CAA evolution. Recently, de la Torre in the context of the vascular dysfunction, frequently associated with Alzheimer's disease, has hypothesized the use of growth factors, specifically FGF-2 and VEGF, to promote neo-angiogenesis as a mean to alleviate the pervasive cerebral endothelial dysfunction. 33 This is in analogy with the application of FGF-2 in human trials for intermittent claudication, a disease that recognizes peripheral vasculopathy as the main causative factor. 34 The findings of this study provide the experimental framework for a similar approach for CAA. In addition, FGF-2, which has been shown to have very promising neuroprotective effects in a number of experimental conditions involving neuronal damage, 35 might exert beneficial effects on neuronal deficits present in advanced CAA as well as in AD.
In summary, these results that indicate a novel role of endogenous FGF-2 in preserving endothelium from Abinduced damages, also imply that its pro-angiogenic activity may be exploited to activate brain neo-angiogenesis in an attempt to reduce the burden of CAA.
Materials and Methods

Cell culture
Post-capillary venular endothelial cells (CVEC) were obtained and cultured as previously described. 20, 31 Mouse aortic endothelial cells (MAE) and MAE transfected with human FGF-2 cDNA (pZIPbFGF) were provided by M Presta (Brescia University, Italy), and cultured as FGF-2 and beta amyloid S Donnini et al reported.
17 pZIPbFGF cells were obtained by transfection of MAE cells with the retroviral expression vector pZIPNeoSV(X) containing a 1.1 kb insert of the human FGF2 cDNA. 36 Chinese hamster ovary (CHO) cells transfected for FGF-R1 were provided by M Presta (University of Brescia, Italy) and cultured as reported. 37 
Cell survival
A total of 1.5 Â 10 3 cells resuspended in 10% serum were seeded in each well of 96 multiplate. After adherence (5-6 h), the supernatant was replaced with a medium containing 0.1% serum (BCS for CVEC and FCS for MAE and pZIPbFGF) 38 and after 24 h cells were incubated with Ab 1-40 or reverse sequence peptide Ab 40-1 (0.5-100 mM). After 48 h, cells were fixed in 100% methanol and stained with Diff-Quik (Mertz-Dade). Total cell number/well was counted at 100 Â magnification. Data are expressed as percentage of cells over basal control or number of cells counted/well.
Cell migration
Chemotaxis experiments were performed with the Boyden chamber technique (48-well microchemotaxis chamber) as previously described. 38 To assess whether Ab was able to influence VEGF-induced migration, cells were pre-incubated with 5 mM Ab 1-40 for 4 h, then studied for their ability to migrate in response to 20 ng/ml VEGF for 4 h. After incubation, filters were fixed and stained with Diff-Quick (Mertz-Dade). The number of cells present in five fields/well was counted at Â 400 magnification. Data are reported as number of cells counted/well.
Caspase-3 activity
A total of 4 Â 10 5 cells were plated in 10% serum, starved (0.1% serum) for 24 h, and then stimulated with 50 mM Ab 1-40/40-1 for 16 h. Enzyme activity was detected in supernatants by measuring the proteolytic cleavage of fluorogenic substrate of caspase-3 (Z-DEVD-R110) in assay buffer provided by the kit. The fluorescence was measured by using SpectraFluor (Tecan) (excitation/emission 485/535) every 30 min within 3 h. Data are reported as relative fluorescence/mg protein7s.e.m. 39 For immunohistochemistry analysis, 15 Â 10 3 cells were plated in 10% serum, starved overnight and then stimulated with Ab 1-40 (0.5 and 5 mM) and Ab 40-1 (5 mM). Medium was removed and the cells were washed with PBS with Ca 2 þ and Mg 2 þ and then fixed in cold acetone for 5 min. Cells were then incubated with primary antibody anti-cleaved caspase-3 (Cell Signaling, Beverly, MA, USA) diluted 1 : 35 in PBS with 0.5% BSA overnight at 41C. Then the secondary antibody (goat-anti-mouse IgG-TRITC diluted 1 : 50) was added for 1 h at room temperature. The cells were mounted in Mowiol (Calbiochem, VWR International srl, Italy) and then observed by fluorescence microscope (Nikon, Eclipse3000).
Tunel assay
Apoptosis was determined by using ApopTag s Plus Fluorescein In Situ Apoptosis Detection Kit (Chemicon) following kit protocol. Briefly, 25 Â 10 3 CVEC cells were seeded on cover slides in a 24 multiwell plate. Cells were starved for 24 h and then stimulated with Ab 1-40 (5 mM), FGF-2 (20 ng/ml) or Ab 40-1 (5 mM) for 16 h. Cells were counterstained with DAPI as indicated by the kit. Original magnification was at Â 400.
Western blot
A total of 3 Â 10 5 cells were plated in 60 mm diameter dishes. After adhesion, cells were serum starved for 24 h, then exposed to test substances following different protocols. To evaluate the effect of Ab peptides on VEGF-induced ERK1/2 phosphorylation, ECs were preincubated with Ab 1-40 (5 mM) for 16 h and then stimulated with 20 ng/ml VEGF for 10 min. To assess the effect of Ab peptides on FGF-2, cells were treated with Ab 1-40 (0.5-50 mM) for 16 h. For Akt phosphorylation cells were exposed to FGF-2 (20 ng/ml) for 15 min in the presence/absence of Ab 1-40 (5 mM). After incubation with test substances, Western blots were performed as described. 16 Results were normalized to those obtained by using an antibody to total ERK1/2 (for phospho-ERK1/2), to actin (for FGF-2) or to total Akt (phospho-Akt).
Immunoprecipitation CVEC (5 Â 10 5 ) were seeded in 60 mm diameter dishes. After adherence cells were harvested (0.1% serum) overnight and then stimulated with Ab 1-40 (5 mM) in the presence/absence of FGF-2 (20 ng/ml) for 15 min. Cells were then lysed and lysates were scraped from the dishes and precleared by centrifugation at 10 000 g for 25 min at 41C. Anti eNOS antibody (5 mg/ml) was then added to the precleared lysates for 2 h at 41C, followed by an overnight incubation at 41C with protein G (50 ml).
Immunoprecipitates were washed twice in 1 ml of sample buffer, boiled for 5 min and separated in SDS/polyacrilamide (8%) gels and electroblotted onto nitrocellulose membranes. Immunoblots were incubated with anti HSP90 antibody.
Determination of nitric oxide synthase (eNOS) activity
NOS activity was measured in CVEC and MAE as previously described, . 20 All determinations were performed in duplicate. NOS activity is expressed as pmol of [ 3 H]-citrulline formed/mg protein.
Microcarrier cell culture
Gelatine-coated cytodex microcarriers were prepared and embedded in a fibrin gel as described. 41 Stimuli (20 ng/ml VEGF, 5 mM Ab 1-40 alone or together with VEGF) were added. Stimuli were replaced after 2 days. At days 1-7 after the polymerization of the gels, the area occupied by capillary-like formations was quantified by an inverted microscope at a magnification of Â 200, using an ocular grid. The area is expressed as the number of grid units required to cover all the pseudocapillary surface. Results are reported as mean area unit7s.e.m.
Heparin binding
10 ml of heparin-acrylic beads were incubated with increasing concentrations of Ab 1-40 (0.5 nM to 50 mM) in 40 ml PBS for 1 h at 371C. Then 25 ng of FGF-2 was added, and the beads were incubated for 2 h at 371C. After incubation, the beads were washed three times with PBS, and bound FGF-2 was removed from the beads by boiling in sample buffer and then separated by SDS-PAGE in 18% polyacrylamide gel. Western blotting was performed with anti-FGF-2 antibody and filters were visualized by enhanced chemiluminescence. Experiment was performed at least three times.
